BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

Running, not enrolling · Phase 2

Conditions studied: Transplant Rejection

In brief

Primary Objectives: * Cohort A: To evaluate the efficacy of BIVV020 in prevention of AMR * Cohort B: To evaluate the efficacy of BIVV020 in treatment of active AMR Secondary Objectives: * To assess the overall efficacy of BIVV020 in prevention or treatment of AMR * To characterize the safety and tolerability of BIVV020 in kidney transplant participants * To characterize the pharmacokinetic (PK) profile of BIVV020 in kidney transplant participants * To evaluate the immunogenicity of BIVV020

Key facts

Study ID

NCT05156710

Run by

Sanofi

People needed

48

Starts

2022-06-09

Expected to finish

2026-10-26

Last updated by the study team

2026-02-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant intended to receive SOC therapy per Investigator's judgment and local practice.
• Cohort A: Participants with chronic kidney disease who will receive a kidney transplant from a living or deceased donor.
• Cohort B: Participants who are kidney transplant recipients diagnosed with active AMR.
• BMI ≤ 40 kg/m2.
• Contraceptive use by women during the treatment period, and for at least 49 weeks after the last administration of IMP (BIVV020 + SOC arm participant) or last treatment period visit (SOC arm participant).
• Contraceptive use by men during the treatment period, and for at least 49 weeks after the last administration of IMP (BIVV020 + SOC arm participant) or last treatment period visit (SOC arm participant).

You may not qualify if…

• Participants who are ABO incompatible with their donors.
• Participants with known active ongoing infection as per below:
• Positive HIV.
• Positive HBV.
• HCV with detectable HCV RNA.
• Within 4 weeks of first study intervention: any serious infection, or any active bacterial infection, or any other infection which is clinically significant in the option of the Investigator, unless it can be confirmed that infection was cleared at least 3 days prior to first study intervention.
• History of active tuberculosis (TB) regardless of treatment.
• Participants with clinical diagnosis of systemic lupus erythematosus (SLE).
• Prior treatment with complement system inhibitor within 5 times the half-life.
• Current enrollment in any other clinical study where the last investigational study treatment administration was within 5 half-lives from study intervention initiation.
• The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Where it is running

• Cedars-Sinai Medical Center- Site Number : 8400100 — Los Angeles, California, United States
• University of California Los Angeles Medical Center- Site Number : 8400103 — Los Angeles, California, United States
• University of California San Francisco - Parnassus Heights- Site Number : 8400001 — San Francisco, California, United States
• Massachusetts General Hospital- Site Number : 8400007 — Boston, Massachusetts, United States
• Brigham & Women's Hospital- Site Number : 8400004 — Boston, Massachusetts, United States
• NYU Langone Medical Center- Site Number : 8400102 — New York, New York, United States
• University of Wisconsin Hospitals and Clinics- Site Number : 8400003 — Madison, Wisconsin, United States
• Investigational Site Number : 1240101 — Vancouver, British Columbia, Canada
• Investigational Site Number : 1240001 — Vancouver, British Columbia, Canada
• Investigational Site Number : 1240002 — London, Ontario, Canada
• Investigational Site Number : 1240003 — Montreal, Quebec, Canada
• Investigational Site Number : 2500007 — Bordeaux, France
• Investigational Site Number : 2500002 — Créteil, France
• Investigational Site Number : 2500001 — Paris, France
• Investigational Site Number : 2500005 — Toulouse, France
• Investigational Site Number : 2760002 — Berlin, Germany
• Investigational Site Number : 2760004 — Essen, Germany
• Investigational Site Number : 2760001 — Munich, Germany
• Investigational Site Number : 3800004 — Bologna, Emilia-Romagna, Italy
• Investigational Site Number : 3800002 — Rome, Lazio, Italy
• Investigational Site Number : 3800001 — Brescia, Lombardy, Italy
• Investigational Site Number : 3800003 — Milan, Milano, Italy
• Investigational Site Number : 7240004 — Barcelona, Barcelona [Barcelona], Spain
• Investigational Site Number : 7240003 — Madrid, Madrid, Comunidad de, Spain
• Investigational Site Number : 7240002 — Madrid, Madrid, Comunidad de, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.